Effects of the ITGA2B Nonsense Mutation (c.2659C > T, p.Q887X) on Platelet Function in a Mouse Model of Glanzmann's Thrombasthenia Generated with CRISPR/Cas9 Technology.
10.19746/j.cnki.issn.1009-2137.2022.02.040
- Author:
Fei YANG
1
,
2
;
Miao JIANG
2
;
Zeng-Hua LIN
3
;
Zhan-Li XIE
4
;
Zhen-Ni MA
2
;
Li YANG
3
;
Hong LIU
3
;
Zhao-Yue WANG
5
;
Lu ZHOU
6
Author Information
1. Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, China
2. Key Laboratory of Thrombosis & Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China.
3. Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, China.
4. Institute of Clinical Medicine Research, Suzhou Science and Technology Town Hospital Affiliated to Nanjing Medical University , Suzhou 215001, Jiangsu Province, China.
5. Key Laboratory of Thrombosis & Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China,E-mail: zwang11@sina.com.
6. Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, China,E-mail: xueyezhoulu2007@sina.com.
- Publication Type:Journal Article
- Keywords:
CRISPR/Cas9;
Glanzmann's thrombasthenia;
mouse model
- MeSH:
Animals;
CRISPR-Cas Systems;
Codon, Nonsense;
Disease Models, Animal;
Fibrinogen/genetics*;
Humans;
Integrin alpha2/genetics*;
Mice;
Oligonucleotides;
Platelet Glycoprotein GPIIb-IIIa Complex/genetics*;
RNA, Guide;
Thrombasthenia/genetics*;
Thrombin/genetics*
- From:
Journal of Experimental Hematology
2022;30(2):559-564
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To construct a mouse model of Glanzmann's thrombasthenia (GT) with ITGA2B c.2659 C>T (p.Q887X) nonsense mutation by CRISPR/Cas9 technology, and then further explore the expression and function of glycoprotein αIIbβ3 on the surface of platelet membrane.
METHODS:The donor oligonucleotide and gRNA vector were designed and synthesized according to the ITGA2B gene sequence. The gRNA and Cas9 mRNA were injected into fertilized eggs with donor oligonucleotide and then sent back to the oviduct of surrogate mouse. Positive F0 mice were confirmed by PCR genotyping and sequence analysis after birth. The F1 generation of heterozygous GT mice were obtained by PCR and sequencing from F0 bred with WT mice, and then homozygous GT mice and WT mice were obtained by mating with each other. The phenotype of the model was then further verified by detecting tail hemorrhage time, saphenous vein bleeding time, platelet aggregation, expression and function of αIIbβ3 on the surface of platelet.
RESULTS:The bleeding time of GT mice was significantly longer than that of WT mice (P<0.01). Induced by collagen, thrombin, and adenosine diphosphate (ADP), platelet aggregation in GT mice was significantly inhibited (P<0.01, P<0.01, P<0.05). Flow cytometry analysis showed that the expression of αIIbβ3 on the platelet surface of GT mice decreased significantly compared with WT mice (P<0.01), and binding amounts of activated platelets to fibrinogen were significantly reduced after thrombin stimulation (P<0.01). The spreading area of platelet on fibrinogen in GT mice was significantly smaller than that in WT mice (P<0.05).
CONCLUSION:A GT mouse model with ITGA2B c.2659 C>T (p.Q887X) nonsense mutation has been established successfully by CRISPR/Cas9 technology. The aggregation function of platelet in this model is defective, which is consistent with GT performance.
